Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy

Identification and Evaluation of the Potential Biomarkers on Circulating Tumor Cells and Tumor Related Rare Cells in Cancer Patients Undergoing Immunotherapy

The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.

Inclusion Criteria:

1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
2. Over 20 years of age.
3. Cancer patients on immune checkpoint inhibitors.

Exclusion Criteria:

1. Subjects who have other cancer history
2. Pregnant females
3. Subjects with active, known or suspected autoimmune disease.
4. Known history of human immunodeficiency virus (HIV)